加载中
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
前收盘价
US$14.34
+US$0.35 · +2.50%
盘前
US$14.66
+US$0.32 · +2.23%
10月12日 4:28 ET
盘中时间采用ET。市场数据可能有所延迟。
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
日内区间
当前US$14.34
52周区间
当前US$14.34
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
57
合理估值
情绪
56
多空交织
风险
45
风险偏高
动量
52
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
日内区间
当前US$14.34
52周区间
当前US$14.34
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 |
|---|---|---|
| 营收 | 3189.3万 USD | 2045.9万 USD |
| 毛利 | 3189.3万 USD | 2045.9万 USD |
| 研究与开发 | 2.25亿 USD | 1.75亿 USD |
| 销售、一般及管理费用 | 4226万 USD | 4208.7万 USD |
| 营业费用 | 2.67亿 USD | 2.17亿 USD |
| 利息收入 | 1366.1万 USD | 1811.8万 USD |
| 利息支出 | 113.6万 USD | 211.8万 USD |
| 折旧和摊销 | 1317.8万 USD | 1534.9万 USD |
| 营业利润 | −2.35亿 USD | −1.97亿 USD |
| 净利润 | −2.03亿 USD | −1.74亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$26.00
上涨空间 81.31%报告持有此股票敞口的交易所交易基金。
ARK Genomic Revolution ETFARKG2199.06万1.07%15.57亿 USD0.75%US$51.30+4.08%
Vanguard Morningstar Total Stock Market ETFVTI1247.37万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM905.85万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF458.61万0.00%954亿 USD0.05%US$235+0.80%
JPMorgan U.S. Tech Leaders ETFJTEK410.97万0.08%48.99亿 USD0.65%US$107.91+1.80%
ALPS Medical Breakthroughs ETFSBIO233.76万1.22%1.91亿 USD0.50%US$55.04+2.03%
iShares Russell 2000 Growth ETFIWO220万0.02%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO214.62万0.01%180亿 USD0.06%US$112.66+0.50%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFJPMorgan U.S. Tech Leaders ETFJTEKALPS Medical Breakthroughs ETFSBIOiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
